• OssDsign AB

  Led · Equity · Nov 2015

  OssDsign develops and markets next-generation bone replacement products based on advanced material science, including patient-specific cranial implants and an off-the-shelf synthetic bone graft for spine surgeries. The company supports the body’s own healing capabilities to improve clinical outcomes across multiple orthopedic indications. OssDsign has a strong commercial presence in the US, Europe and selected Asian countries and its share is traded on Nasdaq First North Growth Market in Stockholm, Sweden. The company is pursuing expansion of its product portfolio and advancement of clinical programs. Recent financing was explicitly intended to fund its efforts to build a global bone graft business and accelerate growth in the US. The company is positioned to use the strengthened financial base to support commercialization and clinical development. OssDsign is a portfolio company of Karolinska Development that develops medical products for craniomaxillofacial indications and is broadening its focus to orthobiologics and spinal surgery. In early March the company presented a new corporate strategy, ASCENT25, intended to accelerate growth, value creation and innovation and achieve positive cash flow by 2025. To support that strategy OssDsign completed a rights issue with preferential rights for existing shareholders, which was oversubscribed. The board exercised an over‑allotment option to carry out a directed new issue, bringing total gross proceeds to SEK 270 million excluding transaction costs. The fundraising outcome is expected to enable strategic investments to expand the product portfolio and sales into additional orthopedic market segments. Karolinska Development, a long‑term investor, subscribed for its pro rata share in the new issue. OssDsign develops and sells regenerative implant solutions intended to improve healing of bone defects. The company intends to use new proceeds to expand sales in Europe and the US and to enter new markets. OssDsign is preparing for a market introduction in Japan, running pre-marketing activities in parallel with the regulatory process and with ethical committee approval in place for surgeons to start building experience. The company is preparing for a listing on Nasdaq First North in 2019, with Erik Penser Bank acting as financial advisor. Karolinska Development is a major backer, holding 25% on a fully diluted basis. The recent financing is intended to support commercialization and geographic expansion rather than research-stage development. OssDsign develops regenerative implants to improve healing of bone defects and deficits in skull, facial and other types of surgery. Its product portfolio includes Craniomosaic for cranioplasty and Sculpter for facial reconstruction. The products are currently available in Germany, the United Kingdom and the Nordic countries, with further expansion in Europe scheduled for 2016. The company is working with regulatory authorities to expand access in new key markets and expects clearance in the US in 2016. Led by CEO Anders Lundqvist, OssDsign plans to use new funding to accelerate market expansion of its craniofacial implant line. The company recently completed an equity financing to support these plans. OssDsign develops patient-specific bioceramic implants for bone healing, starting with its OssDsign Cranio PSI product for skull reconstruction. The company has a registration certificate for production and sales of patient-specific implants and reports very positive results in treated patients to date. After completing a SEK 13.7m rights issue, OssDsign has initiated a clinical multi-center study evaluating clinical outcomes, quality of life, and health economics; first patients have been treated at Karolinska University Hospital. The company is developing a new bioceramic material with a chemical composition similar to bone and aims to transform that technology into differentiated products for bone replacement. Its strategy is to build a niche orthopedics company beginning with sales in skull surgery and extend applications to other areas such as fracture healing. The market for bone replacement products was reported as worth EUR 1bn in 2012.

• TitanX Engine Cooling

  Led · Equity · Mar 2013

  TitanX Engine Cooling supplies cooling solutions for the heavy-truck market. Led by CEO Stefan Nordström, the company serves OEM customers including Daimler, Scania and Volvo. It operates production facilities in Sweden (Mjällby and Linköping) and the US (Jamestown, NY), and recently opened a plant in Jaguariúna, Brazil. Additional plants are planned in Mexico and China. EQT Opportunity acquired the company in 2008 and remains the majority owner. The company secured new investment to support continued growth in key markets.

• Smart Eye

  Led · Equity · Feb 2013

  Smart Eye develops camera-based eye-tracking systems and eye-sensor software, with primary customers in the automotive industry and additional use cases in aerospace test facilities and medical applications. Its main product, Smart Eye Pro, can be equipped with up to eight cameras and targets users requiring high measurement accuracy and flexibility. A second product line, Smart Eye Anti Sleep, is derived from the same technology and has been adapted for automotive requirements. More than 90 percent of the company’s sales are to countries outside Sweden. Management says it needs a financial partner to meet strong international demand and to fund strategic product development and market expansion. The company is based in Gothenburg.

• Pelagicore

  Led · Equity · Sep 2011

  Pelagicore is a technology and product development company focused on Open Source software applications for the automotive in-vehicle infotainment (IVI) industry. The company develops and licenses software intended to reduce the costs and timeframes of IVI development and has participated in industry efforts such as the BMW-initiated GENIVI consortium. Pelagicore was founded in 2009, is based in Gothenburg, and has 10 employees. Its customer base consists mainly of car manufacturers and their suppliers. The company plans to expand its product portfolio and strengthen competitiveness through an international ecosystem of partners. Recent financing is intended to support continued expansion in the automotive industry and to reinforce its market position as a global supplier of Open Source-based IVI platforms.

• Applied Nano Surfaces

  Led · Equity · Dec 2010

  Applied Nano Surfaces has developed a surface treatment technology that produces thin nano-composite coatings delivering extremely low friction and durable anti-wear properties for steel and cast iron components. The method, based on research carried out at Uppsala University between 2000 and 2006, enables manufacturers to cost‑efficiently create coatings to improve energy efficiency in applications where friction-related losses are significant, such as internal combustion engines, bearings, compressors and pumps. The company was founded in 2008 and is led by CEO Mattias Karls, and is based in Uppsala, Sweden. In December 2010 it completed a €1.3m fundraising and also secured a term loan from the Swedish Energy Agency. The round was led by new investor Fouriertransform AB, with participation from existing investors the Sixth AP Fund, Första Entreprenörsfonden and Attentus Göteborg. Applied Nano Surfaces intends to use the capital to continue expansion into new markets and into more application areas.

No current team members are available.